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Abstract
Background. The metabolic syndrome (MS) is associ-
ated with increased prevalence of kidney stones, yet the
speciﬁc stone type remains largely unknown. This study
was conducted to assess whether risk factors associated
with calcium nephrolithiasis increase with individual
characteristics of the MS.
Methods. A retrospective analysis was performed in 109
non-stone-forming subjects and 128 recurrent calcium
stone formers from Dallas, Texas. A separate analysis was
performed in 140 recurrent calcium stone formers from
Bern, Switzerland. Demographic, anthropometric, serum
and urinary proﬁles were measured.
Results. In non-stone formers from Dallas, urinary
calcium (3.6 ± 1.8 to 6.0 ± 2.9 mmol/day, P = 0.0003 for
trend, zero to four features) increased with increasing fea-
tures of the MS. This change was attendant with a signiﬁ-
cant rise in supersaturation index (SI) of calcium oxalate
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(CaOx) (2.76 ± 1.21 to 4.45 ± 1.65, P < 0.0001; zero to
four features). In calcium stone formers from Dallas,
urinary calcium marginally increased (5.2 ± 2.3 to 7.0 ±
4.0 mmol/day, P = 0.09; zero to four features), while
urinary oxalate (356 ± 141 to 504 ± 203 mmol/day, P =
0.001; zero to four features) and SI CaOx (4.46 ± 1.80 to
6.16 ± 3.71, P = 0.009; zero to four features) signiﬁcantly
increased with features of the MS. However, when ad-
justed for confounding variables such as total volume,
age, gender, urine sodium and urine sulfate, urinary
calcium and SI CaOx showed no signiﬁcant changes in
stone formers yet remained signiﬁcant in non-stone
formers. In a separate cohort from Bern, Switzerland
urinary calcium (6.9 ± 3.6 versus 7.0 ± 3.2, P = 0.8) and
SI CaOx (3.37 ± 1.98 versus 4.04 ± 2.78, P = 0.5) did not
differ between subjects with and without the MS.
Conclusions. In non-stone formers, the risk of CaOx
stone formation increases with the number of features of
the MS. However, in stone-forming subjects, the propen-
sity for CaOx precipitation is much higher but is not inde-
pendently associated with increasing features of the MS.
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Introduction
The metabolic syndrome (MS) and obesity are formidable
health burdens in the USA, affecting 20–30% of the
general population [1, 2]. A large cross-sectional study
utilizing data from the third National Health and Nutrition
Examination Survey (NHANES III) found that an increas-
ing number of features of the MS [3] was associated with
an increase in prevalence of self-reported kidney stones
[4]. Similarly, a prospective study in three large cohorts
demonstrated that obesity and weight gain increase the
risk of kidney stone formation [5]. However, the type of
stone and underlying risk factors in individuals with the
MS has yet to be characterized. Previous studies have
shown that excessively acidic urine, the major abnormal-
ity in patients with uric acid nephrolithiasis, is also seen
in non-stone-forming patients with Type II diabetes melli-
tus (T2DM), suggesting that unduly low urine pH may be
an underlying renal manifestation of the MS [6–10]. Fur-
thermore, it has been demonstrated that higher body mass
index (BMI) and T2DM are independent risk factors for
the development of uric acid kidney stones, and the pro-
portion of uric acid stone formation in these individuals is
three times higher than those without such features [11].
However, it is not known whether the reported increase in
prevalence of kidney stones in obese subjects [3, 4] is due
to uric acid nephrolithiasis alone. Since 80 % of kidney
stones consist of calcium oxalate (CaOx) [12, 13], studies
exploring the relationship between urinary risk factors for
calcium stone formation and features of the MS are
critical. Here, we present the biochemical and physico-
chemical characteristics of calcium stone risk in non-
stone-forming subjects and in patients with calcium
stones and their relationship to features of the MS.
Materials and methods
Study participants
We examined three separate cohorts: stone formers and non-stone
formers from Dallas, Texas, USA and stone-formers from Inselspital,
Bern, Switzerland. Data from calcium stone-forming subjects in Dallas
were obtained retrospectively from the Stone Registries at The University
of Texas Southwestern Medical Center. Local advertisements were used
to prospectively recruit non-stone-forming subjects for this study. Stone
analysis showed predominantly CaOx composition. A separate analysis
was performed on a cohort of kidney stone formers from the Inselspital
at the University of Bern, Switzerland. Included in the study were sub-
jects > 21 years old. Excluded were individuals with chronic kidney
disease (creatinine clearance < 40 mL/min), renal tubular acidosis,
chronic diarrhea, primary hyperparathyroidism and urinary tract infec-
tion. All subjects were instructed to hold all medications known to inﬂu-
ence urinary kidney stone proﬁles, such as alkali treatment and thiazide
diuretics, for 1 week prior to inclusion in the study. In all cohorts, sub-
jects with T2DM were permitted to participate in this study if they were
not taking insulin or thiazolidinediones. This study was approved by the
institutional review board at the University of Texas Southwestern
Medical Center at Dallas and the University of Bern. Informed consent
was obtained from all participants. Retrospective and prospective enroll-
ment was conducted sequentially over a 5-year time period.
Data collection and measurements
All participants collected a 24-h urine sample, and the urine container
was kept refrigerated or maintained in an ice chest during the collection.
The urine specimen was obtained while subjects were maintained on an
ad-lib random home diet. At completion of the collection, a fasting
blood specimen was drawn and height, weight and blood pressure (BP)
were measured. The updated deﬁnition of the MS from the American
Heart Association/National Heart, Lung and Blood Institute in 2005 was
utilized to classify features of the MS [3]. The MS was deﬁned by the
presence of three or more of the following: (i) elevated fasting blood
glucose≥ 6 mmol/L or drug treatment for elevated serum glucose,
(ii) elevated BP as systolic BP > 135 mmHg, diastolic BP > 85 mmHg or
drug treatment for hypertension, (iii) elevated fasting serum triglycerides
> 1.70 mmol/L or drug treatment for hypertriglyceridemia, (iv) low
fasting serum high-density lipoprotein (HDL) cholesterol < 1.30 mmol/L
in women and < 1.04 mmol/L in men or drug treatment for low HDL,
(v) abdominal obesity with a waist circumference of > 88 cm in women
and > 102 cm in men. Because waist circumference was not available in
all participants of this study, BMI of≥ 30 kg/m2 was used as criterion
for obesity. BMI is considered a reliable substitute for waist circumfer-
ence since they are highly correlated [14]. Indeed, BMI has been utilized
instead of waist circumference for the deﬁnition of MS in past studies
[15, 16]. Insulin resistance was calculated from fasting serum glucose
concentration and plasma insulin concentration using the homeostasis
model assessment for insulin resistance (HOMA-IR) [17, 18]. This
measurement was only performed in non-stone-forming subjects who
had serum insulin measured prospectively but was not available in the
retrospective evaluation of calcium kidney stone formers.
Analytical procedures
Serum electrolytes, glucose, triglycerides, total cholesterol, HDL choles-
terol, creatinine and uric acid concentrations were measured using an
automated system (CX9ALX; Beckman, Fullerton, CA). Plasma insulin
was determined by enzyme-linked immunosorbent assay (Mercodia, Me-
tuchen, NJ). Urine creatinine was determined using the picric acid
method. Urinary calcium was determined by atomic absorption spec-
troscopy, oxalate by a chromatography system using a carbonate–
bicarbonate eluent and an anion column and phosphorus by ammonium
molybdate-based reaction. Urinary uric acid was analyzed by the urate
oxidase method using an alkalinized aliquot to prevent precipitation.
Urinary sodium and potassium were analyzed by ﬂame emission pho-
tometry, chloride by Labconco buchler chloridometer and sulfate by ion
chromatography. Urine pH and Pco2 were measured by an electrode.
Urinary bicarbonate (HCO− 3was calculated from urine pH and Pco2.
Urinary NH4
+ was determined by glutamate dihydrogenase method. Ti-
tratable acidity (TA) was measured directly using automated burette end
point titration system (Radiometer, Copenhagen, Denmark). Urinary TA
in non-stone-forming subjects was also indirectly calculated from urinary
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constituents according to the method described by Kok et al. [19].
Citrate was calculated by citrate lyase assay, and milliequivalents of
citrate were calculated from urine pH and a pKa of citrate2− /citrate3− of
5.6. Net acid excretion (NAE) was calculated as urine (NH4
+ + TA)−
(citrate2− /3− + HCO3
− ), all expressed in milliequivalents. From these
urinary measures, urinary saturation with respect to CaOx and brushite
(CaHPO4 · 2H2O) was calculated as supersaturation index (SI) by using
the JESS program [20]. SI value of 1 indicates saturation, > 1 supersa-
turation and < 1 undersaturation. In order to account for differences in
urinary volume, SI values were calculated for a theoretical 2 L/day of
urine volume.
Statistical analyses
Categorical comparisons were performed using the χ2 test. Serum trigly-
cerides, HOMA-IR and skewed urinary variables were log transformed
before performing parametric statistical analyses. For normally distribu-
ted continuous variables, comparisons of participants with and without
MS were made with two-sample t-test. For urine NH4
+ /NAE, the Wilcox-
on rank sum test was used. Tests of linear trend were conducted by one-
way analysis of variance with polynomial contrasts. The urine NH4
+ /NAE trend was analyzed with the Jonckheere–Terpstra test. Linear
models were used to examine the relationship between the number of
MS features, the independent variable and the dependent variables urine
calcium and SI CaOx. The linear trends were compared between non-
stone formers and stone formers by evaluating the group-by-MS inter-
action and, in the absence of an interaction, by the group main effect
from these models. Analysis of covariance was also used to further
examine the relationship between SI CaOx and increasing MS features
while adjusting for potential confounding variables. BMI, age, gender,
urine sulfate and creatinine clearance were included as covariates.
Results are expressed as mean and SD unless and otherwise speciﬁed.
Statistical analyses were performed using SAS 9.2 (SAS Institute,
Cary, NC).
Results
Characteristics of non-stone formers from Dallas
A total of 109 non-stone-forming subjects participated in
this study. Demographic characteristics are presented in
Table 1. The mean ( ± SD) age was 43 ± 15 years, and the
mean BMI was 27.6 ± 6.3 kg/m2. The median number of
MS features was 1, and 29.4 % of subjects met criteria for
the MS (i.e. three or more MS features).
Relationship of biochemical proﬁles to the MS in non-
stone-forming subjects from Dallas
A comparison of the anthropometric and biochemical
characteristics of participants with and without the MS is
shown in Table 2. There was no signiﬁcant difference in
gender and ethnic distributions between the two groups.
Subjects with the MS were signiﬁcantly older and had
signiﬁcantly greater serum insulin and HOMA-IR. Com-
pared to participants without the MS, subjects with the MS
had signiﬁcantly higher urinary calcium (5.4 ± 2.7 mmol/
day versus 3.8 ± 1.9 mmol/day; P = 0.003). The 24-h
urinary pH was signiﬁcantly lower in subjects with the MS
(5.67 ± 0.50 versus 6.13 ± 0.44; P < 0.0001). Urinary sulfate
(22.5 ± 8.5 mmol/day versus 18.3 ± 7.7 mmol/day; P =
0.01) and NAE (60.0 ± 28.4 mEq/day versus 37.5 ± 26.5
mEq/day; P = 0.0004) were also signiﬁcantly higher in sub-
jects with the MS. Urinary oxalate, uric acid and citrate did
not differ between the two groups. SI of CaOx (4.26 ± 1.73
versus 2.89 ± 1.29; P = 0.0002) was signiﬁcantly higher in
subjects with the MS compared to those without. However,
SI of brushite did not differ between the two groups.
Demographics, biochemical and physicochemical
characteristics were further stratiﬁed according to the
number of features of the MS as illustrated in Table 3.
Gender and ethnicity did not differ according to the
number of MS features. Age, serum insulin and HOMA-
IR increased with increasing number of features of the
MS. Twenty-four-hour urinary calcium rose with increas-
ing number of features of the MS (P = 0.0003 for trend)
(Figure 1A) but was not signiﬁcant after covariate adjust-
ment for age, gender, urine sulfate and creatinine clear-
ance (Figure 1B). Urinary pH decreased with higher
number of MS characteristics (P < 0.0001 for trend).
Urinary oxalate increased numerically but was not statisti-
cally signiﬁcant (P = 0.06). Uric acid and citrate did not
change signiﬁcantly with increasing numbers of features
of the MS (Table 3). SI of CaOx increased with increasing
MS characteristics Figure (1A and B). SI of brushite did
not change signiﬁcantly with number of characteristics of
the MS (Table 3).
Characteristics of calcium stone-forming subjects from
Dallas
A total of 128 recurrent calcium kidney stone formers
were retrospectively evaluated. Comprehensive demo-
graphic characteristics of the stone-forming population are
shown in Table 4. The mean ( ± SD) age was 43 ± 12
years, and the mean BMI was 29.3 ± 8.4 kg/m2. The
median number of MS features was 2 and 35.9 % of sub-
jects met the criteria for the MS. A number of features of
the MS were retrieved at the time of initial evaluation.
Participants were further subdivided according to the pres-
ence or absence of the MS. Demographic, anthropometric
and biochemical characteristics of these groups are illus-
trated in Table 5. There was no signiﬁcant difference in
gender and ethnic distributions between the two groups.
Table 1. Demographic characteristics of non-stone-forming subjects
from Dallas
Characteristic Value
No. of participants 109
Gender [male/female; n ( % )] 57/52 (52/48)
Ethnicity (White/Asian/Hispanic) 85/12/12
Age (years; mean ± SD) 43 ± 15
Height (cm; mean ± SD) 168 ± 11
Weight (kg; mean ± SD) 79 ± 20
BMI (kg/m2; mean ± SD) 27.6 ± 6.3
Elevated BMI [n ( % )] 31 (28.4)
Elevated fasting blood glucose [n ( % )] 38 (34.9)
Elevated triglycerides [n ( % )] 31 (28.4)
Low HDL [n ( % )] 56 (51.4)
Elevated BP [n ( % )] 35 (32.1)
No. of MS features [median (IQR)] 1 (0–3)
MS [n ( % )] 32 (29.4)
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Table 2. Demographic, anthropometric, serum and urinary characteristics of non-stone-forming subjects from Dallas with and without the MSa
No of MS (N = 77) MS (N = 32) P
Gender, male/female; n ( % ) 38/39 (49/51) 19/13 (59/41) 0.3
Ethnicity, White/Asian/Hispanic; n ( % ) 61/10/6 (79/13/8) 24/2/6 (75/6/19) 0.2
Age, years 39 ± 14 52 ± 14 < 0.0001
BMI, kg/m2 24.9 ± 4.1 34.3 ± 5.6 < 0.0001
Systolic BP, mmHg 116 ± 13 132 ± 16 < 0.0001
Diastolic BP, mmHg 73 ± 10 81 ± 9 0.0005
Serum
Glucose, mmol/L 5.1 ± 0.8 6.6 ± 2.1 0.0007
Triglycerides, mmol/L 1.10 ± 0.81 2.35 ± 1.46 < 0.0001
HDL cholesterol, mmol/L 1.26 ± 0.29 1.00 ± 0.20 < 0.0001
Insulin, pmol/L 53 ± 30 114 ± 62 < 0.0001
HOMA-IR 1.0 ± 0.6 2.2 ± 1.2 < 0.0001
Urine
Total volume, L/day 1.87 ± 0.87 2.18 ± 1.34 0.2
Calcium, mmol/day 3.8 ± 1.9 5.4 ± 2.7 0.003
Oxalate, mmol/day 306 ± 98 340 ± 119 0.1
Uric acid, mmol/day 2.98 ± 1.12 3.25 ± 0.99 0.2
pH 6.13 ± 0.44 5.67 ± 0.50 < 0.0001
Citrate, mEq/day 9.8 ± 4.1 8.8 ± 3.9 0.2
Sulfate, mmol/day 18.3 ± 7.7 22.5 ± 8.5 0.01
NAE, mEq/day 37.5 ± 26.5 60.0 ± 28.4 0.0004
NAE, mEq/day (calculated) 35.4 ± 23.7 58.4 ± 31.7 0.0006
NH4
+ /NAE. 0.73 (0.57–0.94) 0.84 (0.38–1.43) 0.0008
Creatinine clearance, mL/s 1.88 ± 0.53 2.17 ± 0.75 0.06
Supersaturation indices
SI CaOx (volume adjusted) 2.89 ± 1.29 4.26 ± 1.73 0.0002
SI Br (volume adjusted) 0.93 ± 0.56 0.95 ± 0.70 0.9
aValues are expressed as mean ± SD.
Table 3. Demographic, anthropometric, serum and urinary characteristics of non-Stone-forming subjects from Dallas and number of features of the
MSa
Number of MS features
P for trend0 (N = 29) 1 (N = 28) 2 (N = 20) 3 (N = 12) ≥4 (N = 20)
Gender, male/female; n ( % ) 13/16 (45/55) 14/14 (50/50) 11/9 (55/45) 7/5 (58/42) 12/8 (60/40) 0.8
Ethnicity, White/Asian/Hispanic 24/3/2 22/4/2 15/3/2 10/1/1 14/1/5 0.6
Age, years 38 ± 12 35 ± 13 47 ± 15 50 ± 18 54 ± 11 < 0.0001
BMI, kg/m2 22.9 ± 3.5 24.6 ± 3.7 28.1 ± 3.6 32.8 ± 4.5 35.2 ± 6.1 < 0.0001
Systolic BP, mmHg 113 ± 9 111 ± 11 126 ± 16 131 ± 18 133 ± 15 < 0.0001
Diastolic BP, mmHg 72 ± 9 70 ± 11 78 ± 10 77 ± 10 82 ± 8 < 0.0001
Serum
Glucose, mmol/L 4.9 ± 0.4 4.9 ± 0.6 5.7 ± 1.1 5.8 ± 1.4 7.0 ± 2.4 < 0.0001
Triglycerides, mmol/L 0.73 ± 0.35 0.96 ± 0.62 1.81 ± 1.07 1.23 ± 0.49 3.01 ± 1.43 < 0.0001
HDL cholesterol, mmol/L 1.46 ± 0.27 1.14 ± 0.25 1.16 ± 0.22 1.05 ± 0.26 0.97 ± 0.16 < 0.0001
Insulin, pmol/L 42 ± 24 50 ± 38 72 ± 33. 91 ± 34. 129 ± 72 < 0.0001.
HOMA-IR 0.8 ± 0.4 0.9 ± 0.5 1.3 ± 0.6 1.7 ± 0.6 2.5 ± 1.4 < 0.0001.
Urine
Total volume, L/day 1.95 ± 0.94 1.66 ± 0.79 2.05 ± 0.85 2.27 ± 1.29 2.13 ± 1.39 0.2
Calcium, mmol/day 3.6 ± 1.8 3.7 ± 2.0 4.3 ± 1.9 4.6 ± 2.2 6.0 ± 2.9 0.0003
Oxalate, mmol/day 292 ± 101 302 ± 86 329 ± 109 341 ± 113 340 ± 124 0.06
Uric acid, mmol/day 2.84 ± 0.91 3.06 ± 1.31 3.07 ± 1.17 3.30 ± 0.83 3.21 ± 1.09 0.2
pH 6.23 ± 0.44 6.19 ± 0.44 5.91 ± 0.38 5.87 ± 0.51 5.55 ± 0.47 < 0.0001
Citrate, mEq/day 8.9 ± 4.2 10.9 ± 4.2 9.8 ± 3.8 7.5 ± 4.2 9.6 ± 3.5 0.5
Sulfate, mmol/day 17.0 ± 6.7 17.3 ± 8.4 21.6 ± 7.3 19.3 ± 4.8 24.5 ± 9.6 0.002
NAE, mEq/day 33.6 ± 25.3 32.2 ± 25.9 50.8 ± 25.5 52.4 ± 26.7 64.8 ± 29.1 < 0.0001
NAE, mEq/day (calculated) 32.5 ± 22.8. 31.1 ± 22.8. 45.7 ± 24.1. 47.7 ± 21.8. 64.8 ± 35.4. < 0.0001.
NH4
+ /NAE 0.85 (0.66–0.97) 0.74 (0.53–1.09) 0.62 (0.52–0.79) 0.58 (0.54–0.69) 0.56 (0.46–0.65) < 0.0001
Creatinine clearance, mL/s 1.77 ± 0.32 1.87 ± 0.55 2.08 ± 0.68 2.10 ± 0.90 2.20 ± 0.67 0.008
Supersaturation indices
SI CaOx (vol adjusted) 2.76 ± 1.21 2.74 ± 1.45 3.30 ± 1.15 3.95 ± 1.89 4.45 ± 1.65 < 0.0001
SI Br (volume adjusted) 0.91 ± 0.50 0.97 ± 0.67 0.92 ± 0.50 1.07 ± 0.90 0.88 ± 0.57 0.9
aValues are expressed as mean ± SD except where otherwise noted.
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Relationship of biochemical proﬁles to the MS in calcium
stone-forming subjects from Dallas
Urinary calcium, sulfate and citrate did not differ between
the two groups. However, urinary pH (6.14 ± 0.42 versus
5.91 ± 0.44; P = 0.005) was lower, while urinary oxalate
(353 ± 141 versus 454 ± 206 mmol/day; P = 0.004) and
NAE (43.7 ± 22.0 mEq/day versus 58.0 ± 32.0 mEq/day;
P = 0.009) were higher in kidney stone formers with the
MS than in those without. NH4
+ /NAE was lower in
kidney stone formers with the MS [0.79 (0.68–0.92)
versus 0.68 (0.60–0.82); P = 0.02]. Creatinine clearance
signiﬁcantly differed between those with or without the
MS (1.77 ± 0.47 versus 2.05 ± 0.73 mL/min; P = 0.02).
However, creatinine clearance ranged between 40 and 60
mL/min in only ﬁve patients. SI of CaOx was higher in
stone formers with the MS than those without (5.47 ± 3.0
versus 4.45 ± 1.94; P = 0.04). SI of brushite did not differ
between the two groups.
Calcium stone-forming subjects were further stratiﬁed
according to the number of features of the MS as rep-
resented in Table 6. Age and ethnicity did not differ
according to the number of MS features. BMI, systolic
and diastolic BP increased according to the number of
features of the MS. Urinary pH decreased (P = 0.002
for trend), urinary NAE increased (P = 0.0004 for trend)
but NH4
+ /NAE decreased (P = 0.001 for trend) with in-
creasing number of features of the MS. Creatinine
clearance also progressively increased (from 101 ± 27 to
143 ± 43 mL/min; P = 0.0004 for trend) with increasing
features of the MS (Table 6). Mean 24-h urinary
calcium did not change with increasing MS features
(Figure 1A and 1B) but urinary oxalate increased
Fig. 1. Trends in urinary calcium and Supersaturation index of calcium oxalate (CaOx). (A) Unadjusted. (B) Adjusted for total volume, age, gender,
urine sodium and urine sulfate. Data are presented as mean and 95% conﬁdence interval. P-values represent tests of linear trends for each group.
Unadjusted and adjusted urinary calcium and SI CaOx values were higher in stone formers than in non-stone formers at across of features of the MS
(P≤ 0.001).
Table 4. Demographic characteristics of calcium stone-forming subjects
from Dallas
Characteristic Value
No of participants 128
Gender [male/female; n ( % )] 72/56 (56/44)
Ethnicity (White/Asian/Hispanic/American Indian) 118/2/6/2
Age (years; mean ± SD) 43 ± 12
Height (cm; mean ± SD) 171 ± 10
Weight (kg; mean ± SD) 87 ± 27
BMI (kg/m2; mean ± SD) 29.3 ± 8.4
Elevated BMI [n ( % )] 42 (32.8)
Elevated fasting blood glucose [n ( % )] 31 (24.2)
Elevated triglycerides [n ( % )] 42 (32.8)
Low HDL [n ( % )] 88 (68.8)
Elevated BP [n ( % )] 56 (43.8)
No. of MS features [median (IQR)] 2 (0–4)
MS [n ( % )] 46 (35.90)
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signiﬁcantly (P = 0.001 for trend). SI of CaOx also in-
creased signiﬁcantly with increasing characteristics of
the MS (4.46 ± 1.80–6.16 ± 3.7; P = 0.009 for trend)
(Figure 1A) but was not signiﬁcant after covariate ad-
justment for age, gender, urine sodium, urine sulfate
and creatinine clearance (Figure 1B).
Table 5. Demographic, anthropometric, serum and urinary characteristics of calcium stone-forming subjects from Dallas with and without the MSa
No MS (N = 82) MS (N = 46) P
Gender, male/female; n ( % ) 44/38 (52/48) 28/18 (60/40) 0.4
Ethnicity, White/Asian/Hispanic/American Indian 75/1/4/2 43/1/2/0 0.7
Age, years 42 ± 12 45 ± 11 0.2
BMI, kg/m2 25.9 ± 5.1 35.4 ± 9.6 < 0.0001
Systolic BP, mmHg 121 ± 14 128 ± 13 0.01
Diastolic BP, mmHg 75 ± 9 82 ± 9 0.001
Serum
Glucose, mmol/L 5.0 ± 0.4 5.8 ± 1.5 0.0004
Triglycerides, mmol/L 1.14 ± 0.58 2.70 ± 1.58 < 0.0001
HDL cholesterol, mmol/L 1.35 ± 0.45 1.07 ± 0.20 < 0.0001
Urine
Total volume, L/day 1.87 ± 1.00 2.19 ± 1.33 0.2
Calcium, mmol/day 5.8 ± 2.9 6.1 ± 3.5 0.50
Oxalate, mmol/day 353 ± 141 454 ± 206 0.004
Uric acid, mmol/day 3.28 ± 1.12 3.79 ± 1.52 0.05
pH 6.14 ± 0.42 5.91 ± 0.44 0.005
Citrate, mEq/day 7.5 ± 4.6 8.0 ± 5.7 0.6
Sulfate, mmol/day 17.9 ± 7.6 20.1 ± 10.2 0.2
NAE, mEq/day (calculated) 43.7 ± 22.0 58.0 ± 32.0 0.009
NH4
+ /NAE 0.79 (0.68–0.92) 0.68 (0.60–0.82) 0.02
Creatinine clearance, mL/s 1.77 ± 0.47 2.05 ± 0.73 0.02
Supersaturation indices
SI CaOx (volume adjusted) 4.45 ± 1.94 5.47 ± 3.00 0.04
SI Br (volume adjusted) 1.53 ± 0.87 1.45 ± 0.91 0.6
aValues are expressed as mean ± SD.
Table 6. Demographic, anthropometric, serum and urinary characteristics of calcium stone-forming subjects from Dallas and number of features of
the MSa
Number of MS features
P for
trend0 (N = 21) 1 (N = 32) 2 (N = 29) 3 (N = 22) ≥4 (N = 24)
Gender, male/female; n ( % ) 7/14 (36/67) 14/18 (44/56) 23/6 (79/21) 13/9 (59/41) 15/9 (63/37) 0.01
Ethnicity, White/Asian/Hispanic/American
Indian
20/0/1/0 30/1/1/0 25/2/0/2 19/1/2/0 24/0/0/0 0.4
Age, years 41 ± 11 39 ± 11 46 ± 13 47 ± 12 43 ± 10 0.1
BMI, kg/m2 22.3 ± 2.8 25.0 ± 3.2 29.4 ± 5.9 30.5 ± 6.3 40.0 ± 9.9 < 0.0001
Systolic BP, mmHg 114 ± 9 121 ± 17 125 ± 12. 128 ± 13 128 ± 13 0.001
Diastolic BP, mmHg 70 ± 5 74 ± 10 79 ± 10 81 ± 8 83 ± 11 < 0.0001
Serum
Glucose, mmol/L 4.9 ± 0.3 4.9 ± 0.4 5.1 ± 0.5 5.2 ± 0.4 6.4 ± 1.9 < 0.0001
Triglycerides, mmol/L 0.81 ± 0.27 1.00 ± 0.42 1.54 ± 0.69 2.46 ± 1.29 2.91 ± 1.82 < 0.0001
HDL cholesterol, mmol/L 1.76 ± 0.52 1.33 ± 0.37 1.07 ± 0.18 1.07 ± 0.21 1.06 ± 0.19 < 0.0001
Urine
Total volume, L/day 1.7. ± 0.97 1.84 ± 1.16 2.00 ± 0.86 1.66 ± 0.70 2.68 ± 1.58 0.02
Calcium, mmol/day 5.2 ± 2.3 5.4 ± 2.4 6.6 ± 3.5 5.2 ± 2.5 7.0 ± 4.0 0.09
Oxalate, mmol/day 356 ± 141 336 ± 126 373 ± 159 399 ± 198 504 ± 203 0.001
Uric acid, mmol/day 2.96 ± 0.90 3.23 ± 1.14 3.57 ± 1.20 3.20 ± 1.31 4.34 ± 1.50 0.001
pH 6.23 ± 0.40 6.15 ± 0.44 6.05 ± 0.41 5.95 ± 0.37 5.88 ± 0.50 0.002
Citrate, mEq/day 7.0 ± 3.3 8.3 ± 4.8 7.0 ± 5.0 6.1 ± 3.3 9.6 ± 6.9 0.3
Sulfate, mmol/day 17.2 ± 7.4 17.2 ± 7.9 19.1 ± 7.6 16.3 ± 9.3 23.5 ± 9.8 0.03
NAE, mEq/day (calculated) 37.4 ± 18.8 41.3 ± 22.7 50.8 ± 22.0 52.7 ± 26.5 63.1 ± 36.3 0.0004
NH4
+ /NAE 0.87 (0.73–
0.98)
0.83 (0.69–
0.96)
0.72 (0.65–
0.82)
0.74 (0.61–
0.81)
0.65 (0.60–
0.93)
0.001
Creatinine clearance, mL/s 1.68 ± 0.45 1.80 ± 0.48 1.77 ± 0.45 1.67 ± 0.57 2.38 ± 0.72 0.0004
Supersaturation indices
SI CaOx (volume adjusted) 4.46 ± 1.80 4.01 ± 1.81 4.93 ± 2.12 4.71 ± 1.74 6.16 ± 3.71 0.009
SI Br (volume adjusted) 1.39 ± 0.81 1.47 ± 0.80 1.71 ± 0.98 1.36 ± 0.78 1.54 ± 1.02 0.7
aValues are expressed as mean ± SD except where otherwise noted.
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Our tests of group-by-MS interaction do not allow us to
conclude that non-stone formers and stone formers have
differing trends, whether adjusted or unadjusted (inter-
action P-values for urine calcium: P = 0.5 unadjusted, P =
0.4 adjusted; SI CaOx: P = 0.9 unadjusted, P = 0.9 ad-
justed). However, the differences between non-stone
formers and stone formers remained irrespective of the
number of MS features (group main effect for urine
calcium: P = 0.001 unadjusted, P = 0.0004 adjusted; SI
CaOx: P = 0.0005 unadjusted, P = 0.0007 adjusted)
(Figure 1A and 1B).
Anthropometric characteristics and biochemical proﬁles
from Bern, Switzerland
A total of 140 additional recurrent calcium kidney stone
formers from a separate cohort were retrospectively evalu-
ated and divided into subjects without the MS and those
with the MS (Table 7). BMI, systolic BP and diastolic BP
were signiﬁcantly higher in subjects with the MS. Serum
glucose and triglyceride concentrations were signiﬁcantly
higher, and serum HDL was signiﬁcantly lower in those
with the MS than in those without (Table 7). Urinary
calcium and oxalate did not differ between the two
groups of calcium stone formers. Accordingly, SI of
CaOx and brushite did not differ between the two groups.
Discussion
One principal ﬁnding of this study is increased risk of
CaOx crystallization (SI CaOx) with increasing features
of the MS (Table 3 and 6). However, this risk cannot be
independently attributed to the MS. The MS likely acts
through other factors such as age [21], gender [22, 23],
urine sodium [24] and urine sulfate [25–27], which is
known to inﬂuence the risk of CaOx stone formation
(Figure 1B). Furthermore, differences in SI CaOx
between non-stone formers and stone formers are main-
tained irrespective of the number of features of the MS
(Figure 1A and 1B). Urinary calcium and SI CaOx were
higher in stone formers than in non-stone formers as the
number of features of the MS increased. Although the
slope remained similar, the difference between the two
groups was signiﬁcant (P≤ 0.001). This strongly supports
that a plethora of underlying heterogeneous pathophysio-
logical abnormalities in hypercalciuric calcium stone
formers, such as intestinal hyperabsorption of calcium,
disturbed bone calcium balance and renal calcium leak
prevail diminishing the contribution of MS features on
hypercalciuria [28–31].
Therefore, while we can demonstrate that the MS is
associated with increased urinary calcium excretion and
the physicochemical risk of CaOx stone formations in
both non-stone formers and stone formers, such an effect
cannot be consistently detected on urinary calcium
excretion and/or CaOx saturation in these subjects when
adjusted for variables known to affect urinary calcium
[21–27]. We propose that while the MS inﬂuences
calcium excretion and CaOx supersaturation, it does not
independently exert a large effect on calciuria. This is
unlike unduly acidic urine, the principle determinant of
urinary uric acid crystallization, which was found to be
independently related to the MS in the general kidney
stone-forming population and more speciﬁcally in patients
with established uric acid nephrolithiasis [6, 32]. These
results were supported by additional studies in normal
subjects and diabetic non-stone formers who exhibited an
association between the MS and low urinary pH [9, 10].
In animal and cell culture models, the potential
Table 7. Demographic, anthropometric, serum and urinary characteristics of calcium stone-forming subjects from Bern with and without the MSa
No MS (N = 111) MS (N = 29) P
Gender, male/female; n ( % ) 90/21 (81/19) 26/3 (90/10) 0.4
Age, years 48 ± 14 49 ± 10 0.8
BMI, kg/m2 25.0 ± 3.8 30.7 ± 6.0 < 0.0001
Systolic BP, mmHg 137 ± 20 146 ± 17 0.03
Diastolic BP, mmHg 86 ± 11 95 ± 15 0.003
Serum
Glucose, mmol/L 5.1 ± 0.8 5.7 ± 1.1 0.01
Triglycerides, mmol/L 1.11 ± 0.45 2.24 ± 0.80 < 0.0001
HDL cholesterol, mmol/L 1.39 ± 0.32 0.99 ± 0.18 < 0.0001
Urine
Total volume, L/day 2.08 ± 0.77 2.19 ± 1.23 0.7
Calcium, mmol/day 6.9 ± 3.7 7.0 ± 3.2 0.8
Oxalate, mmol/dayb 298 ± 138 327 ± 116 0.6
Uric acid, mmol/day 3.27 ± 1.21 3.68 ± 1.12 0.09
pH 6.07 ± 0.81 6.14 ± 0.68 0.6
Citrate, mEq/day 9.4 ± 8.3 9.4 ± 5.9 0.9
Sulfate, mmol/day 24.5 ± 17.7 25.4 ± 11.5 0.7
NAE, mEq/day (calculated) 66.8 ± 40.8 69.5 ± 43.7 0.9
Creatinine clearance, mL/s 1.97 ± 0.58 2.27 ± 0.67 0.02
Supersaturation indices
SI CaOx (volume adjusted) 3.37 ± 1.98 4.04 ± 2.78 0.5
SI Br (volume adjusted) 1.35 ± 0.92 1.59 ± 0.73 0.6
aValues are expressed as mean ± SD.
bOxalate only available in 25 subjects with no MS and six subjects with the MS.
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pathophysiological link between the MS and low urinary
pH was attributed to increased fatty acid provision to the
renal proximal tubule leading to lipotoxicity and resulting
in impaired ammonium production and secretion [33, 34].
A separate unadjusted analysis was performed in the
stone-forming population from Bern, Switzerland. Similar
to the results from Dallas, urinary calcium did not signiﬁ-
cantly differ between stone formers with and without the
MS (Table 7). On the contrary, no difference in urinary
oxalate, and consequently SI CaOx, was seen in Bern
stone formers with and without the MS. This result was
unlike the signiﬁcantly higher urinary oxalate in Dallas
stone formers with the MS. A limitation was that only 31
urinary oxalate measurements were able to be measured
with an established assay.
Our result is signiﬁcant since it was performed in a
cohort of established kidney stone formers followed in
kidney stone clinics. Although previous population-based
studies [4, 5, 35] established the relationship between the
MS and kidney stone disease, the diagnosis of kidney
stones was based on self-reported history of kidney
stones. In addition, validation of self-reported kidney
stone history was only performed in a very small percen-
tage of participants in the Health Professionals Follow-up
Study and Nurse’s Health Study I [5, 35]. On the contrary,
one report in a large number of stone-forming diabetic
and non-diabetic patients showed that the relative percen-
tage of CaOx stone formation was lower in diabetic stone
formers in whom BMI was signiﬁcantly higher than in
non-diabetics [36].
One potential link between the MS and nephrolithiasis
is hyperinsulinemia, an invariable feature of the MS. Hy-
perinsulinemia and obesity act in opposing directions on
renal tubular calcium handling. While hyperinsulinemia
could potentially cause hypercalciuria [37, 38], this effect
can be opposed by body weight [39] and calciotropic
hormone status [40]. Additional studies using the hyperin-
sulinemic euglycemic clamp in both non-stone-forming
and calcium stone-forming subjects are needed to under-
stand the potential role of insulin in urinary calcium
excretion.
The association of MS features with urinary oxalate
excretion has not been studied. One study suggested that
larger body size is associated with higher urinary oxalate
excretion in normal subjects, which may be attributed to
increased endogenous oxalate production [41]. In the
present study, urinary oxalate was much higher in calcium
stone formers with the MS (Table 5). The increase in
urinary oxalate with features of the MS was also higher in
the kidney stone-forming population (Table 6), which
may be responsible for signiﬁcantly higher unadjusted SI
CaOx (Figure 1A). However, the magnitude of this rise
was not sufﬁcient to change the urinary supersaturation of
CaOx when adjusted for age, gender, urine sodium, urine
sulfate and creatinine clearance in stone formers
(Figure 1B). One advantage of epidemiological studies is
the inclusion of a large number of subjects, but a limit-
ation is the absence of urinary stone risk proﬁles. More-
over, in many epidemiological studies, kidney stone
incidence was based solely on self-report and there was a
lack of identiﬁcation of kidney stone composition. Our
study overcame some of these limitations, yet the sample
size was smaller in comparison. However, a notable limit-
ation of our study was that it is cross-sectional in nature.
Nevertheless, in general the risk of CaOx nephrolithiasis
coincides with urinary supersaturation proﬁles [42]. To
substantiate this link, long-term studies with kidney stone
incidence as a primary end point are needed.
Conclusions
In subjects without a history of kidney stones, the risk of
CaOx stone formation increases with the number of fea-
tures of the MS. In subjects with established history of
calcium stones, the risk of CaOx precipitation is much
higher overall but is not independently associated with the
number of features of the MS.
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